Cost effectiveness analysis of abacavirlamivudine versus tenofoviremtricitabine combination therapy as part of highly active antiretroviral therapy in treatment naive HIV-infected patients

Pierre Giguere
Introduction: Current recommendations for the treatment of HIV include the use of dual nucleoside reverse transcriptase inhibitors, namely abacavir/lamivudine or tenofovir/emtricitabine. This study is to compare the cost-effectiveness of these two alternatives in the treatment of HIV treatment-naive patients. Methods: A review of the literature was performed to identify relevant randomized controlled trials and economic models. The economic model described by Richter using maximal virologic response and rate of failure as efficacy parameters was adapted...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.